PriceTargets.com logo

Pharming Group - PHAR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $37.00
  • Forecasted Upside: 270.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$10.00 As of 04/19/2024 06:21 PM ET
▲ +0.67 (7.18%)

This chart shows the closing price for PHAR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pharming Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PHAR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PHAR

Analyst Price Target is $37.00
▲ +270.00% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Pharming Group in the last 3 months. The average price target is $37.00, with a high forecast of $37.00 and a low forecast of $37.00. The average price target represents a 270.00% upside from the last price of $10.00.

This chart shows the closing price for PHAR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Pharming Group. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$37.00Low
8/3/2023HC WainwrightReiterated RatingBuy$37.00Low
3/29/2023Royal Bank of CanadaInitiated CoverageOutperformLow
3/28/2023OppenheimerBoost TargetOutperform$36.00 ➝ $40.00Low
3/27/2023HC WainwrightReiterated RatingBuy$37.00Low
2/22/2023HC WainwrightReiterated RatingBuy$37.00Low
2/16/2023HC WainwrightReiterated RatingBuy$37.00Low
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 6 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 6 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Pharming Group logo
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Read More

Today's Range

Now: $10.00
Low: $9.33
High: $10.18

50 Day Range

MA: $11.05
Low: $9.62
High: $12.95

52 Week Range

Now: $10.00
Low: $9.27
High: $16.71

Volume

6,272 shs

Average Volume

2,652 shs

Market Capitalization

$671.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.16

Frequently Asked Questions

What sell-side analysts currently cover shares of Pharming Group?

The following Wall Street analysts have issued stock ratings on Pharming Group in the last year: HC Wainwright.
View the latest analyst ratings for PHAR.

What is the current price target for Pharming Group?

1 Wall Street analysts have set twelve-month price targets for Pharming Group in the last year. Their average twelve-month price target is $37.00, suggesting a possible upside of 284.8%. HC Wainwright has the highest price target set, predicting PHAR will reach $37.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $37.00 for Pharming Group in the next year.
View the latest price targets for PHAR.

What is the current consensus analyst rating for Pharming Group?

Pharming Group currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PHAR will outperform the market and that investors should add to their positions of Pharming Group.
View the latest ratings for PHAR.

What other companies compete with Pharming Group?

Other companies that are similar to Pharming Group include PureTech Health, Y-mAbs Therapeutics, Praxis Precision Medicines, Bicycle Therapeutics and Aerovate Therapeutics. Learn More about companies similar to Pharming Group.

How do I contact Pharming Group's investor relations team?

Pharming Group's physical mailing address is DARWINWEG 24, LEIDEN P7, 2333 CR. The company's listed phone number is 31-71-524-7400 and its investor relations email address is [email protected]. The official website for Pharming Group is www.pharming.com. Learn More about contacing Pharming Group investor relations.